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Abstract
In this study, we demonstrated the importance of telomerase protein expression and determined the relationships among 
telomerase, endothelin-1 (ET-1) and myofibroblasts during early and late remodeling of parenchymal and vascular areas 
in usual interstitial pneumonia (UIP) using 27 surgical lung biopsies from patients with idiopathic pulmonary fibrosis (IPF). 
Telomerase+, myofibroblasts α-SMA+, smooth muscle cells caldesmon+, endothelium ET-1+ cellularity, and fibrosis 
severity were evaluated in 30 fields covering normal lung parenchyma, minimal fibrosis (fibroblastic foci), severe (mural) 
fibrosis, and vascular areas of UIP by the point-counting technique and a semiquantitative score. The impact of these 
markers was determined in pulmonary functional tests and follow-up until death from IPF. Telomerase and ET-1 expres-
sion was significantly increased in normal and vascular areas compared to areas of fibroblast foci. Telomerase and ET-1 
expression was inversely correlated with minimal fibrosis in areas of fibroblast foci and directly associated with severe 
fibrosis in vascular areas. Telomerase activity in minimal fibrosis areas was directly associated with diffusing capacity of 
the lung for oxygen/alveolar volume and ET-1 expression and indirectly associated with diffusing capacity of the lungs 
for carbon monoxide and severe fibrosis in vascular areas. Cox proportional hazards regression revealed a low risk 
of death for females with minimal fibrosis displaying high telomerase and ET-1 expression in normal areas. Vascular 
dysfunction by telomerase/ET-1 expression was found earlier than vascular remodeling by myofibroblast activation in 
UIP with impact on IPF evolution, suggesting that strategies aimed at preventing the effect of these mediators may have 
a greater impact on patient outcome.
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Idiopathic pulmonary fibrosis (IPF) is a devastating 
chronic fibrosing interstitial pneumonia of unknown etiol-
ogy that typically increases in prevalence with advanced 
age, characterized by excessive collagen deposition and 
irreversible remodeling of the lung parenchyma (1,2). The 
histologic pattern associated with IPF is the usual interstitial 
pneumonia (UIP), characterized by patchy and temporally 
heterogeneous fibrosis with excessive extracellular matrix 
(ECM) and honeycomb change, interspersed with normal 
and collapsed areas (1). Although the etiology of IPF/UIP 
is not understood, many investigators hypothesize that 
dysregulated communication between injured epithelial 
cells and activated mesenchymal cells represents an im-
portant factor in its pathogenesis (3). Vascular changes 
are another event frequently observed in IPF (4,5). In 
previous studies, we found a direct relationship between 
progressive vascular occlusion by collagen/elastic fiber 
deposition and tissue remodeling in surgical lung biopsies 
from patients with IPF (4,5). These findings probably are 
the consequence of persistent myofibroblast activation 
by mesenchymal cells, resulting in a heterogeneous 
fibroblast phenotype, intermediate between fibroblasts 
and smooth muscle cells (6). Although heterogeneity in 
fibroblast phenotype is evident, a subset of differentiated 
activated fibroblasts is characterized by the expression of 
alpha-smooth muscle actin (α-SMA) (7). Depending on 
the precise stimulatory milieu, fibroblasts either transform 
to myofibroblasts or proliferate, resulting in vascular oc-
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clusion or areas of fibroblastic foci, which are thought to 
be the sites of active ECM, collagen and elastic synthesis, 
and are considered to be the leading edge of fibrosis and 
vascular remodeling (8). In this regard, endothelin-1 (ET-1) 
is one of the more potent inducers of collagen deposition, 
with its fibrogenic effects being central in wound healing 
and tissue repair. A major role of ET-1 involves transition of 
quiescent fibroblasts to an “activated” phenotype, whereby 
matrix production and wound contraction are important 
consequences (9). Telomerase is a specialized polymerase 
that adds telomere repeats to the ends of chromosomes by 
using its intrinsic RNA component as a template, thereby 
compensating for the telomere loss that normally occurs 
with each cell division (10). Telomerase has been shown 
to be essential for unlimited cell proliferation and has been 
linked to immortality (11). Bleomycin-induced lung injury 
and fibrosis is also known to induce telomerase activity in 
the affected lung tissue and isolated lung fibroblasts (12). 
The fibroblasts isolated from such lungs undergoing fibro-
sis show increased intrinsic proliferative capacity and are 
able to differentiate into α-SMA expressing myofibroblasts, 
which are also a key source of cytokines with inflammatory 
and fibrogenic properties (13,14). An injured lung fibroblast 
population may contain telomerase expressing cells with an 
extended life span, which could contribute to the observed 
increased numbers of lung fibroblasts (12).
In view of these considerations suggesting an interac-
tion among telomerase, endothelium and myofibroblast 
activation, the aim of the present study was to evaluate 1) 
whether telomerase, ET-1 and myofibroblast α-SMA are 
expressed in vascular and parenchymal areas of UIP; 2) to 
verify if the measures of mediator expression correlate with 
some measure of fibrosis, and 3) to determine the impact of 
the resultant parenchymal/vascular remodeling on patient 
survival. It was hypothesized that in UIP, a devastating 
chronic fibrosing interstitial pneumonia, the mediators under 
study exert their effect by influencing parenchyma/vascular 
remodeling/fibrosis with impact on patient outcome.
Material and Methods
This research was approved by the Institutional Ethics 
and Scientific Committees (protocol No. 0960/08) and all 
patients gave written informed consent to participate in 
the study. 
Open lung biopsies
Pulmonary specimens were obtained by surgical lung 
biopsy from 27 patients with IPF/UIP (14 males and 13 
females; mean age 64 ± 1.4 years), according to criteria 
outlined in the American Thoracic Society/European Re-
spiratory Society International Multidisciplinary Consensus 
Classification of idiopathic interstitial pneumonias (1). Only 
specimens from patients who fulfilled these consensus 
criteria were included. Three lung specimens obtained by 
open surgical biopsy from each patient were collected ac-
cording to the normal, intermediate and more affected areas 
in different parts of the lung determined by high-resolution 
computed tomography. The histologic UIP pattern of IPF 
was characterized by the patchy subpleural and paraseptal 
distribution of parenchymal injury. Temporal heterogeneity 
was seen at low magnification, with alternating areas of 
normal lung parenchyma with septal fibro-myxoid tissue 
(fibroblastic foci), honeycomb and vascular thickening.
Baseline characteristics
The pulmonary function tests included vital capacity, 
forced expiratory volume in 1 s (FEV1), forced vital capac-
ity (FVC), FEV1/FVC ratio 100X, total lung capacity (TLC), 
residual volume (RV), and carbon monoxide transfer factor 
(diffusing capacity of the lung for carbon monoxide, DLCO). 
The percentages of TLC, RV, and RV/TLC were measured 
by the helium dilution method using a Master Screen ap-
paratus (Erich Jaeger GmbH, Germany). The DLCO and 
DLCO/alveolar volume (VA) were assessed by the single 
breath holding helium dilution method (15). Lung function 
results (Table 1) are reported as the percentage of patient 
lung function compared to predicted values for a standard-
ized healthy population. In all patients, the arterial partial 
pressure of carbon dioxide (PaCO2) and partial pressure 
of oxygen (PaO2) were also measured at rest.
Immunohistochemistry
A standard peroxidase technique was used, with Har-
ris’s hematoxylin as the counterstain, to identify telom-
erase+ epithelial cells, ET-1+ endothelium and α-SMA+ 
Table 1. Clinical data of the patients.
Variables Idiopathic pulmonary fibrosis
Age at biopsy (years) 64.5 ± 7.4
Gender (males/females) 13/14
Spirometry
FEV1 (% predicted) 78 ± 4.4
FVC (% predicted) 69.5 ± 3.5
FEV1/FVC 20 ± 8.8
TLC (% predicted) 79 ± 5
RV (% predicted) 102 ± 15.9
TLC/RV (%predicted) 44.2 ± 3.4
DLCO (% predicted) 59.8 ± 8
DLCO/VA (% predicted) 59 ± 11.7
PaCO2 60.2 ± 3.7
PaO2 38.1 ± 1.3
Data are reported as means ± SEM. FEV1 = forced expiratory 
volume in 1 s; FVC = forced vital capacity; TLC = total lung ca-
pacity; RV = residual volume; DLCO = diffusing capacity of the 
lung for carbon monoxide; VA = alveolar volume; PaCO2 = partial 
pressure of carbon dioxide; PaO2 = partial pressure of oxygen.
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myofibroblasts and caldesmon+ smooth muscle cells in 
normal tissue, fibroblastic foci and vascular areas of UIP. 
Since the α-SMA antibody stains myofibroblasts as well 
as smooth muscle cells, which are a regular component 
of arteries, the caldesmon (C21) antibody sc-58700 was 
specifically used to characterize these cells. All antibod-
ies used were biotinylated rabbit polyclonal antibodies. 
Anti-telomerase, anti-ET-1, anti-αSMA and anti-caldesmon 
polyclonal antibodies (Santa Cruz Biotechnology, Inc., USA) 
were incubated with tissue sections at 1:100 dilution. The 
Max Polymer Novolink amplification kit (Leica, Newcastle 
Inc., UK) was used for signal amplification and 3,3′-diamin-
obenzidine tetrachloride (0.25 mg dissolved in 1 mL 0.02% 
hydrogen peroxide) was used as a precipitating substrate 
for signal detection. The specificity of primary antibodies 
was confirmed by appropriate reagent controls (omitting 
the primary antibody or substituting non-immune serum 
for the primary antibody in the staining protocol), which 
revealed no staining.
Histomorphometry
Regional differences between samples from the same 
patient in the three lung specimens obtained by open surgi-
cal biopsy in each patient were evaluated for telomerase+ 
epithelium, ET-1+ endothelium, α-SMA+ myofibroblasts, 
caldesmon+ smooth muscle cells, and fibrosis severity in 
30 fields by the point-counting technique (16) and a semi-
quantitative score (4). As previously described, the histologic 
pattern of UIP was characterized by alternating areas of 
normal lung parenchyma, minimal fibrosis (fibroblastic 
foci), severe (mural) fibrosis, honeycombing, and vascular 
thickening. At 400X magnification, 30 fields were chosen 
from across multiple sites accounting/adjusting for cellularity 
or as number of positively staining cells per mesenchymal 
tissue. In other words, normal lung parenchyma, minimal 
fibrosis (fibroblastic foci), severe (mural) fibrosis, and vas-
cular areas present in UIP in each field were determined 
according to the number of points hitting mesenchymal 
tissue, as a proportion of the total grid area. The number 
of positive cells within the normal lung parenchyma, mini-
mal fibrosis (fibroblastic foci), severe (mural) fibrosis, and 
vascular areas were then counted. The immunostaining 
cellularity was determined as the number of positive cells 
in each field divided by the normal lung parenchyma, mini-
mal fibrosis (fibroblastic foci), severe (mural) fibrosis, and 
vascular areas. The final results are reported as means ± 
SEM of 3 lung specimens from each patient in 30 random, 
non-coincident microscopic fields.
The severity of fibrosis was assessed by semiquantita-
tive analysis in UIP areas of 1) mild interstitial thickening by 
fibroblastic foci (minimal fibrosis, Figure 1A and B), and 2) 
severe mural-organizing fibrosis with honeycombing and 
foci of actively proliferating fibroblasts and myofibroblasts 
(severe fibrosis, Figure 1C-F).
Interobserver comparisons were performed for 20% of the 
slides by 2 observers (E.R.P. and V.L.C.). The coefficient of 
variation for the interobserver error of cell count was <5%.
Statistical analysis
Data are reported as means ± SEM with 95% confidence 
intervals. ANOVA with the Bonferroni test were used to 
analyze the relationship between continuous variables and 
the residuals were examined to ensure that their distribution 
was approximately normal. The relationship between the 
immunostaining cellularity was evaluated by Pearson’s cor-
relation. Actuarial survival was estimated using the Kaplan-
Meier method and compared using the log-rank test. Cox 
proportional hazards regression was used to ascertain the 
individual contribution of factors associated with survival 
and to compare adjusted survival between groups. The 
statistical program used was SPSS 18.0 (SPSS Inc., USA). 
The level of significance was set at 5% in all tests.
Results
Telomerase activation
Immunochemical staining of epithelium telomerase+ in 
normal (Figure 2B), minimal fibrosis (Figure 2C), severe 
fibrosis (Figure 2D), and vascular (Figure 2F) areas of UIP, 
appears as brownish cells. Epithelium telomerase+ im-
munostaining was more exuberant in normal and vascular 
areas than in fibrosing areas of the histologic pattern of UIP 
than in control areas (Figure 2A and E).
Quantitative analysis confirmed the morphologic dis-
tribution of telomerase+ epithelium expression (Table 2). 
Telomerase+ epithelium was significantly overexpressed 
in normal and vascular areas than in UIP fibrosing and 
control areas.
Myofibroblasts and smooth muscle cell replication
α-SMA+ myofibroblasts in normal (Figure 3A), fibros-
ing (Figure 3C) and vascular (Figure 3E) areas of UIP 
and control areas (Figure 3G), when stained by immuno-
histochemistry, appear as brownish cells. α-SMA+ myofi-
broblasts were more prominent than smooth muscle cells 
caldesmon+ in vascular (Figure 3F) than fibrosing (Figure 
3D) and control (Figure 3H) areas. Normal areas did not 
present α-SMA+ myofibroblasts or caldesmon+ smooth 
muscle cells (Figure 3B).
Quantitative analysis confirmed the morphologic distri-
bution of α-SMA+ myofibroblasts and caldesmon+ smooth 
muscle cells (Table 2). Interestingly, α-SMA+ myofibroblasts 
were significantly more increased than caldesmon+ smooth 
muscle cells in vascular areas of UIP (P < 0.001).
Endothelium activation
ET-1+ endothelium in normal (Figure 4B), minimal 
(Figure 4C) and severe (Figure 4D) fibrosing, as well as 
vascular (Figure 4F) areas of UIP, when stained by immu-
nohistochemistry, appears as brownish cells. Numerous 
668 E.R. Parra et al.
www.bjournal.com.brBraz J Med Biol Res 45(7) 2012
cells in normal and vascular areas expressed ET-1 when 
compared to fibrosing areas of the UIP histologic pattern 
and control areas (Figure 4A and E).
Quantitative analysis confirmed the morphologic distri-
bution of ET-1 expression that was significantly increased 
in normal and vascular areas of UIP when compared to 
fibrosing areas (Table 2).
Association between mediators
A direct association was found between telomerase and 
Figure 1. Degree of fibrosis in the pattern of usual interstitial pneumonia (UIP). UIP minimal fibrosis is characterized by interstitial 
thickening (arrows) and by fibroblastic foci (FF) (A and B) and UIP severe fibrosis is characterized by severe mural-organizing fibrosis 
(arrows) (C) with foci of actively proliferating fibroblasts and myofibroblasts (FF) (D) and honeycombing (stars) (E). Vascular (VAS) 
representation is observed in the middle of pulmonary fibrosis (F). Hematoxylin and eosin.
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ET-1 expression in vascular areas of UIP (r = 0.45; P = 0.03). 
An inverse association was found between telomerase and 
ET-1 expression in normal and minimal fibrosis areas of 
UIP (r = -0.42; P = 0.03). Telomerase and ET-1 expression 
were positively associated with vascular areas (r = 0.54; 
P = 0.004) and negatively associated with minimal fibrosis 
and normal areas (r = -0.44; P = 0.02) of UIP.
Association between mediators and fibrosis severity
Telomerase and ET-1 expression were inversely cor-
related with minimal fibrosis in normal and fibroblast foci 
areas (r = -0.38; P = 0.04 and r = -0.39; P = 0.03, respec-
Figure 2. Telomerase expression in control areas (A and E) and in a normal area (B), in an area of minimal fibrosis (arrows) (C), of 
fibroblastic foci (FF) of severe fibrosis (D) and in vascular (F) areas of usual interstitial pneumonia (UIP), when stained by immunohis-
tochemistry. Numerous cells are observed in the different areas of UIP pattern when compared with the control areas. 
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tively) and directly associated 
with severe fibrosis in vascular 
areas (r = 0.41; P = 0.03 and r 
= 0.54; P = 0.004) of UIP.
Association between media-
tors and functional tests
A direct association was 
found between diffusing capac-
ity of the lung for oxygen/al-
veolar volume (DLCO/VA) and 
telomerase activity (r = 0.49; 
P = 0.01) in minimal fibrosis 
areas. An indirect association 
was found between DLCO and 
severe fibrosis in vascular areas 
displaying high ET-1 expression 
(r = -0.74; P = 0.02).
Survival analysis
The median follow-up was 
42.70 months. Ten patients 
were still alive and 17 died 
from causes related to IPF. 
ROC curve analysis showed 
that the optimum cut-off point 
of expression was 14.55% for 
telomerase and 12.54% for 
ET-1. These cut-off points resulted in a significant differ-
ence in Kaplan-Meier curves. The 5-year survival rate of 
patients with minimal fibrosis in vascular areas displaying 
ET-1 ≤12.54% was 57.49 vs 31.13% in the group with 
minimal fibrosis displaying higher ET-1 levels (P < 0.01). 
The 5-year survival rate of patients with minimal fibrosis in 
vascular areas displaying telomerase ≤14.55% was 59.55 
vs 28.88% in the group with minimal fibrosis and higher 
telomerase levels (P < 0.01).
Several combinations of clinical and morphological 
variables were analyzed to generate a mathematical model 
with an impact on IPF patient survival. The results of the 
best combination, determined by Cox model analysis, ap-
pear in Table 3. The following variables showed a significant 
impact on patient survival: gender, age, fibrosis severity, 
telomerase in UIP normal lung parenchyma, telomerase 
in minimal (fibroblastic foci) fibrosis, ET-1 in normal lung 
parenchyma, and minimal (fibroblast foci) fibrosis. Multi-
variate analyses showed a low risk of death for females, 
UIP normal lung parenchyma or minimal (fibroblastic foci) 
fibrosis displaying high telomerase and ET-1 expression in 
UIP normal lung parenchyma areas.
Discussion
We investigated the participation of telomerase and the 
factors responsible for its activation or suppression in the 
fibrotic process found in pulmonary specimens obtained by 
surgical lung biopsy from patients with IPF. Specifically, we 
investigated telomerase and ET-1 expression in alveolar 
epithelium, endothelium, and myofibroblast cells present in 
normal lung parenchyma, minimal (fibroblast foci) fibrosis 
and vascular areas of UIP to verify the impact of these 
markers on the remodeling/fibrosis process. In the present 
study, telomerase and ET-1 were significantly increased in 
normal lung parenchyma and vascular areas compared to 
fibroblast foci areas of UIP. Unexpectedly, myofibroblast 
α-SMA+ expression was more prominent than smooth 
muscle caldesmon+ cells in vessels. Interestingly, we found 
a positive association between telomerase and ET-1 in UIP 
vascular areas, whereas a negative association was found 
between telomerase and ET-1 in normal lung parenchyma. 
A positive association was found between telomerase and 
myofibroblast α-SMA in UIP vascular areas. In addition, the 
expression of these mediators correlated with the measure-
ment of fibrosis degree, suggesting that they exert their 
effect by influencing remodeling/fibrosis in UIP.
The current study revealed that telomerase increases 
myofibroblast activation in vascular areas of UIP. In fact, 
telomerase can be expressed by different types of cells 
and its presence indicates not only a persistent activity to 
maintain a supply of activated cells (e.g., fibroblasts), but is 
also important in the regulation of cell proliferation (17,18), 
apoptosis (19,20), and cell differentiation (21,22). Although 
Table 2. Histomorphometric markers and cellularity in non-fibrosing lung tissue (control) and 
different areas of fibrosing lung (usual interstitial pneumonia, UIP).
Lung tissue Telomerase α-SMA Caldesmon Endothelin-1
Non-fibrosing lung (control)
Septal areas 0.78 ± 0.42 0 0 0.01 ± 0.02
Vascular areas 0.01 ± 0.02 9.57 ± 2.90 5.2 ± 1.15 0.0003 ± 0.0003
Fibrosing lung (UIP)
Normal lung parenchyma 17.8 ± 6.7+  0 0 17.2 ± 6.4#
Minimal fibrosis 7.4 ± 2.1 8.2 ± 3.7 0.002 ± 0.0005§ 5.7 ± 2.2
Severe (mural) fibrosis 6.4 ± 2.5 12.0 ± 6.6 0.06 ± 0.001§ 7.2 ± 2.9
Vascular areas 18.2 ± 7.2+ 51.7 ± 10.4* 0.45 ± 0.02§ 18.0 ± 4.3#
Data are reported as means ± SEM percent of markers for 3 lung specimens obtained by open 
surgical biopsy from each patient (10 random, non-coincident microscopic fields were analyzed 
in each specimen). All lung specimens were analyzed for epithelial, myofibroblast, endothelial 
and smooth muscle cells from normal lung parenchyma, and minimal fibrosis (fibroblastic foci), 
severe (mural) fibrosis and vascular areas of UIP for percentage of telomerase, α-SMA, calde-
smon, and endothelin-1 fractional areas. +Telomerase expression values in UIP normal lung 
parenchyma and vascular areas differed significantly from minimal (fibroblastic foci) and severe 
(mural) fibrosis (P < 0.01). *α-SMA expression values in UIP vascular areas were significantly 
different from normal lung parenchyma and fibrosis areas (P < 0.01). §Caldesmon expression 
values in UIP fibrosis and vascular areas differed significantly from normal lung parenchyma (P 
< 0.001). Endothelin-1 expression values in normal lung parenchyma and vascular areas dif-
fered significantly from fibrotic and control areas (P < 0.01). All markers in UIP were significantly 
increased compared to non-fibrosing control lungs (P < 0.0001). ANOVA with the Bonferroni test 
were used for statistical analysis.
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Figure 3. Alpha-smooth muscle actin (α-SMA) (A, C, E, G) and caldesmon (B, D, F, H) expression in normal (A, B), 
fibroblastic foci (FF) of fibrosing (C, D) and vascular (E, F) areas of usual interstitial pneumonia (UIP) pattern, and 
vascular control areas (G, H) stained by immunohistochemistry. α-SMA+/myofibroblasts are more prominent than 
caldesmon+ smooth muscle cells in vascular areas than in fibrosing and control areas. Normal areas do not show 
α-SMA+ myofibroblasts or caldesmon+ smooth muscle cells. 
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telomerase activity is a nonspecific signal of cell prolifera-
tion involving different cell types besides fibroblasts, this 
last assumption does not disagree with our results, which 
show an influence of telomerase expression on vessels and 
prognosis. Our findings agree with the study of Nozaki et al. 
(12) who demonstrated that bleomycin-induced lung injury 
and fibrosis are also known to induce telomerase activity in 
the affected lung tissue and isolated lung fibroblasts. The ac-
tivity, however, is expressed only during the period of active 
fibrosis, and appears to be localized primarily in fibroblasts 
Figure 4. Endothelial ET-1+ expression in control areas (A, E) and in normal (B), minimal (C, arrows) and severe (D) fibrosing, showing 
a fibroblastic foci (FF) as well as vascular (F) areas of usual interstitial pneumonia (UIP) pattern when stained by immunohistochem-
istry. Numerous cells in normal and vascular areas expressed endothelin-1 when compared to fibrosing areas of the UIP and control 
areas. Endothelin-1 immunohistochemistry.
Vascular activity in idiopathic pulmonary fibrosis 673
www.bjournal.com.br Braz J Med Biol Res 45(7) 2012
rather than myofibroblasts (23). The activity also declines 
with increased passaging in vitro, which is associated 
with increased differentiation into myofibroblasts. These 
studies suggest that the increased enzyme activity could 
be secondary to higher cell division rates and therefore 
the increase in telomerase activity would be secondary to 
the inflammatory and fibrotic process instead of its cause. 
The factors responsible for regulating telomerase activity 
in these tissues and cells are mostly unknown. More recent 
data from our group have shown that abnormal expression 
of telomerase/apoptosis limits type II alveolar epithelial cell 
replication in the early remodeling of UIP (24). In fact, we 
found that epithelial telomerase expression in normal lung 
parenchyma and fibroblastic foci areas was lower than 
in normal septal areas, probably reflecting the loss and 
shortening of telomeres activity. It is tempting to speculate 
about the existence of a specific checkpoint beyond which 
loss of telomerase activity due to injurious stimuli and/or 
inherited mutations may lead to loss of epithelial cells and 
promote genomic instability. Activation of telomerase after 
the onset of genomic instability, coupled with a repeatedly 
injurious microenvironment, may affect the physiological 
differentiation of normal alveolar epithelial progenitors 
towards a transformed mesenchymal phenotype, resulting 
in abnormal reepithelization in normal parenchymal areas 
and contributing to the fibrogenic process characterized by 
fibroblastic foci. Telomerase would inhibit the senescence 
of many normal cells, such as epithelial and mesenchymal 
cells, and most probably would increase the incidence of 
tumors and fibrosis in the patient. Thus, carcinogenesis and 
fibrogenesis may be similar processes respectively involving 
epithelial and mesenchymal (fibroblasts) neoplastic cells. 
We also found that telomerase and ET-1 expres-
sion were positively associated with vascular tissue and 
negatively associated with normal lung parenchyma and 
fibroblast focus areas of UIP. ET-1 can also be synthesized 
by endothelial and epithelial cells, vascular smooth muscle 
cells, airway epithelium, granulocytes, and macrophages 
(25). Moreover, increased concentrations and biosynthesis 
of ET-1 were demonstrated in the lungs of patients with 
pulmonary hypertension and systemic sclerosis (26). Fur-
thermore, preproendothelin-1 messenger RNA is elevated 
in airway epithelial cells, proliferating type II pneumocytes, 
endothelial cells, and inflammatory cells present in IPF 
(27,28). The increased cell population expressing ET-1 
and telomerase may indicate a continuous stimulation 
and transformation of these cells. In fact, we found a more 
evident expression in epithelial cells of normal alveolar 
areas, reflecting not only the stress to which these cells 
were submitted but also a probable attempt to maintain a 
large population to avoid alveolar collapse, as previously 
demonstrated by our group (24). We also found that many 
epithelial cells and myofibroblasts present in fibroblast 
focus areas expressed ET-1 and telomerase showing a 
high activity of these areas. Actually, ET-1 plays a role in 
several stages of wound healing: stimulating fibroblast dif-
ferentiation and collagen metabolism, promoting the wound 
healing response by the production of collagens IV, V and 
VII, involvement in the reconstitution of the basement mem-
brane and appropriate wound closure and other unknown 
effects on different types of cells (29,30).
Our study has clinical consequences. In order to estab-
lish the relevance of these findings to the evolution of the 
patients, the mediators under study were evaluated as a 
function of fibrosis severity and physiological testing. We 
found a direct association between DLCO/VA and minimal 
fibrosis areas displaying high telomerase activity and be-
tween DLCO and severe fibrosis areas of UIP displaying 
Table 3. Cox proportional hazards regression to ascertain the individual contribution of clinical and morphological fac-
tors associated with survival and to compare adjusted survival between groups [-2 log likelihood = 28.90; chi-square 
= 38.26; P < 0.0001].
  β SE Wald test P value Exp (β) 95%CI for Exp (β)
Lower Upper
Gender -3.74 1.48 6.38 0.01 41.94 2.31 761.02
Age (years) 1.02 0.34 8.94 0.003 2.78 1.42 5.43
UIP fibrosis 9.26 0.01
UIP severe (mural) fibrosis -9.70 3.26 8.87 0.003 0.00 0.00 0.03
UIP minimal (fibroblastic foci) fibrosis -12.04 3.98 9.16 0.002 0.00 0.00 0.01
Telomerase in UIP minimal fibrosis -1.85 0.97 3.60 0.05 6.35 0.94 42.78
Telomerase in UIP normal lung parenchyma 6.05 2.35 6.62 0.01 0.002 0.00 0.23
Endothelin-1 in UIP normal lung parenchyma -5.13 1.81 8.00 0.005 0.006 0.00 0.20
Endothelin-1 in UIP minimal (fibroblast foci) fibrosis 5.72 2.13 7.24 0.007 0.003 0.00 0.21
UIP = usual interstitial pneumonia; β = beta coefficient; SE = standard error; Exp (β) = exponential beta; CI = confi-
dence interval.
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high ET-1 expression. Although hypoxia is universal in IPF 
patients, decreases in DLCO caused by a defect in gas 
transfer certainly present in the pulmonary parenchyma 
of UIP, also contribute to hypoxemia. These functional 
changes observed are probably explained in part by the 
vascular involvement. The expression of these mediators 
probably represents another step in the wound healing 
process in IPF. We believe that high expression of these 
markers is crucial to maintain the activity of parenchymal 
injury by the regulation of compromised vascular tone. Many 
lines of evidence suggest that telomerase activation under 
chronic hypoxia may result in enhanced and sustained 
smooth muscle proliferation and vessel wall remodeling, 
findings characteristic of proliferative vascular disorders, 
such as pulmonary hypertension (31). On the other hand, 
the continuous ET-1 stimulus from the endothelium and 
smooth muscle of vascular cells activates the proliferation 
and the remodeling process of these vessels. Clearly, in 
our study poor patient survival was associated with high 
vascular expression of ET-1 and telomerase, suggesting 
that a major damage to vessels leads to more parenchymal 
alterations during the development of pulmonary fibrosis 
caused by maintained hypoxia.
In conclusion, telomerase activity increases endothelial 
and myofibroblast activation in early remodeling/fibrosis 
of IPF with impact on evolution, suggesting that strategies 
aimed at preventing the effect of these mediators may have 
a greater impact on patient outcome.
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